LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Home・Aktien・Biogen Inc

Biogen Inc

Geschlossen

BrancheGesundheitswesen

140.29 0.24

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

140.04

Max

141.94

Schlüsselkennzahlen
By Trading Economics
Einkommen	394M 635M
Verkäufe	215M 2.6B
KGV Branchendurchschnitt	12.653 35.733
EPS	3.02
Gewinnspanne	23.995
Angestellte	7,605
EBITDA	457M 1B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+20.72% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	29. Okt. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	442M 19B
Vorheriger Eröffnungskurs	140.05
Vorheriger Schlusskurs	140.29

Nachrichtenstimmung

By Acuity

31%

69%

92 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

118.15 / 121.17 Unterstützung & Widerstand

Biogen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Sept. 2025, 09:30 UTC

Akquisitionen, Fusionen, Übernahmen

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6. Sept. 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. Sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. Sept. 2025, 20:37 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5. Sept. 2025, 20:37 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5. Sept. 2025, 20:36 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5. Sept. 2025, 20:36 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5. Sept. 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5. Sept. 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5. Sept. 2025, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5. Sept. 2025, 20:20 UTC

Ergebnisse

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5. Sept. 2025, 19:23 UTC

Market Talk

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5. Sept. 2025, 19:22 UTC

Ergebnisse

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5. Sept. 2025, 19:17 UTC

Market Talk

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5. Sept. 2025, 18:59 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5. Sept. 2025, 18:35 UTC

Market Talk

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5. Sept. 2025, 17:25 UTC

Market Talk

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5. Sept. 2025, 17:20 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5. Sept. 2025, 17:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Sept. 2025, 17:17 UTC

Market Talk

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5. Sept. 2025, 17:03 UTC

Market Talk

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5. Sept. 2025, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5. Sept. 2025, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5. Sept. 2025, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5. Sept. 2025, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5. Sept. 2025, 16:37 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

5. Sept. 2025, 16:37 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Energy Roundup: Market Talk

5. Sept. 2025, 16:37 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5. Sept. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. Sept. 2025, 16:16 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Biogen Inc Prognose

Kursziel

By TipRanks

20.72% Vorteil

12-Monats-Prognose

Durchschnitt 169.81 USD 20.72%

Hoch 260 USD

Tief 118 USD

Basierend auf 26 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Biogen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

26 ratings

Buy

Halten

Sell

Basierend auf 26 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Biogen Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

118.15 / 121.17Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

92 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.